Viatris Swats Away Concerns Over Divestment Valuations

As US-Based Firm Updates On Glatiramer And Botox Biosimilar

Viatris remains committed to completing the sale of its global biosimilars unit to Biocon Biologics, while continuing efforts to generate up to $9bn in pre-tax proceeds by the end of 2023 from divestments.

Dollars (David Wall/Alamy Stock Photo)
Rising rates are no concern to Viatris currently • Source: Shutterstock (Alamy Stock Photo)

Viatris has moved to allay concerns of finding fair value in a challenging market for the non-core assets it is earmarking to sell, as the firm continues along its strategy of generating up to $9bn in pre-tax proceeds by the end of 2023.

In February, the company announced that it was offloading its global biosimilars unit to Biocon Biologics in a deal package...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Strategy

More from Business

Repurposed Generics For Rare Diseases: Janet Woodcock Proposes Shortcut

A Duke-Margolis working group is developing ideas to enable non-profit firms to seek US FDA approval for new indications for off-patent medicines. The former acting commissioner thinks citizen petitions might be the fastest route.

Kashiv Joins Forces With MS Pharma In MENA For Omalizumab

 
• By 

Kashiv BioSciences has struck a deal with MS Pharma to market its omalizumab biosimilar rival to Xolair in the MENA region.

Civica Pairs With Fresenius Kabi To Supply Stelara Biosimilar

 
• By 

US non-profit Civica has announced a partnership with Fresenius Kabi to supply a Stelara rival, revealing pricing details for its exclusive unbranded version of Kabi’s Otulfi biosimilar that will be available from the start of next year.